• Journal Articles 2008 -


    • Holzner S, Brenner S, Atanasov AG, Senfter D, Stadler S, Nguyen CH, Fristiohady A, Milovanovic D, Huttary N, Krieger S, Bago-Horvath Z, Wever O de, Tentes I, Ozmen A, Jager W, Dolznig H, Dirsch VM, Mader RM, Krenn L, et al (2018). Intravasation of SW620 colon cancer cell spheroids through the blood endothelial barrier is inhibited by clinical drugs and flavonoids in vitro. Food Chem Toxicol 111: 114–124
    • Hong J, Fristiohady A, Nguyen CH, Milovanovic D, Huttary N, Krieger S, Hong J, Geleff S, Birner P, Jaeger W, Ozmen A, Krenn L, Krupitza G (2018). Apigenin and Luteolin Attenuate the Breaching of MDA-MB231 Breast Cancer Spheroids Through the Lymph Endothelial Barrier in Vitro. Front Pharmacol 9: 220
    • Hosmann A, Ritscher LC, Burgmann H, Oesterreicher Z, Jager W, Poschner S, Knosp E, Reinprecht A, Gruber A, Zeitlinger M (2018). Concentrations of Cefuroxime in Brain Tissue of Neurointensive Care Patients. Antimicrob Agents Chemother 62: e02164-17


    • Bauer M, Wulkersdorfer B, Karch R, Philippe C, Jäger W, Stanek J, Wadsak W, Hacker M, Zeitlinger M, Langer O (2017). Effect of P-glycoprotein inhibition at the blood-brain barrier on brain distribution of (R)-[C-11]verapamil in elderly vs. young subjects. Br J Clin Pharmacol 83: 1991–1999
    • Böhmdorfer M, Szakmary A, Schiestl RH, Vaquero J, Riha J, Brenner S, Thalhammer T, Szekeres T, Jäger W (2017). Involvement of UDP-glucuronosyltransferases and sulfotransferases in the excretion and tissue distribution of resveratrol in mice. Nutrients 9: 1347
    • Englinger B, Kallus S, Senkiv J, Heilos D, Gabler L, Schoonhoven S van, Terenzi A, Moser P, Pirker C, Timelthaler G, Jäger W, Kowol CR, Heffeter P, Grusch M, Berger W (2017). Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer. J Exp Clin Cancer Res 36: 122
    • Jamil QUA, Jaerapong N, Zehl M, Jarukamjorn K, Jäger W (2017). Metabolism of curcumin in human breast cancer cells: Impact of sulfation on cytotoxicity. Planta Med 83: 1028–1034
    • Maier-Salamon A, Elgendy SA, Meyer B, Vossen M, Thalhammer T, Thalhammer F, Jäger W (2017). Pharmacokinetics of flucloxacillin and its metabolites in patients with renal failure: Impact on liver toxicity. Int J Clin Pharmacol Ther 55: 701–711
    • Monzote L, Lackova A, Staniek K, Steinbauer S, Pichler G, Jäger W, Gille L (2017). The antileishmanial activity of xanthohumol is mediated by mitochondrial inhibition. Parasitology 144: 747–759
    • Nguyen CH, Huttary N, Atanasov AG, Chatuphonprasert W, Brenner S, Fristiohady A, Hong J, Stadler S, Holzner S, Milovanovic D, Dirsch VM, Kopp B, Saiko P, Krenn L, Jäger W, Krupitza G (2017). Fenofibrate inhibits tumour intravasation by several independent mechanisms in a 3-dimensional co-culture model. Int J Oncol 50: 1879–1888
    • Oesterreicher Z, Minichmayr I, Sauermann R, Marhofer D, Lackner E, Jäger W, Maier-Salamon A, Schwameis R, Kloft C, Zeitlinger M (2017). Pharmacokinetics of doripenem in plasma and epithelial lining fluid (ELF): comparison of two dosage regimens. Eur J Clin Pharmacol 73: 1609–1613
    • Pichler C, Ferk F, Al-Serori H, Huber W, Jäger W, Waldherr M, Misik M, Kundi M, Nersesyan A, Herbacek I, Knasmueller S (2017). Xanthohumol prevents DNA damage by dietary carcinogens: Results of a human intervention trial. Cancer Prev Res 10: 153–160
    • Poschner S, Maier-Salamon A, Zehl M, Wackerlig J, Dobusch D, Pachmann B, Sterlini KL, Jäger W (2017). The impacts of genistein and daidzein on estrogen conjugations in human breast cancer cells: A targeted metabolomics approach. Front Pharmacol 8: 699
    • Poschner S, Zehl M, Maier-Salamon A, Jäger W (2017). Simultaneous quantification of estrogens, their precursors and conjugated metabolites in human breast cancer cells by LC-HRMS without derivatization. J Pharm Biomed Anal 138: 344–350
    • Sissung TM, Ley AM, Strope JD, McCrea EM, Beedie S, Peer CJ, Shukla S, Velkinburgh J van, Reece K, Troutman S, Campbell T, Fernandez E, Huang P, Smith J, Thakkar N, Venzon DJ, Brenner S, Lee W, Merino M, Luo J, Jäger W, Price DK, Chau CH, Figg WD (2017). Differential expression of OATP1B3 mediates unconjugated testosterone influx. Mol Cancer Res 15: 1096–1105
    • Stadler S, Nguyen CH, Schachner H, Milovanovic D, Holzner S, Brenner S, Eichsteininger J, Stadler M, Senfter D, Krenn L, Schmidt WM, Huttary N, Krieger S, Koperek O, Bago-Horvath Z, Brendel KA, Marian B, Wever O de, Mader RM, Giessrigl B, Jäger W, Dolznig H, Krupitza G. (2017). Colon cancer cell-derived 12(S)-HETE induces the retraction of cancer-associated fibroblast via MLC2, RHO/ROCK and Ca2+ signalling. Cell Mol Life Sci 74: 1907–1921
    • Stieger B, Mahdi ZM, Jäger W (2017). Intestinal and hepatocellular transporters: Therapeutic effects and drug interactions of herbal supplements. Annu Rev Pharmacol Toxicol 57: 399–416
    • Vossen MG, Knafl D, Haidinger M, Lemmerer R, Unger M, Pferschy S, Lamm W, Maier-Salamon A, Jäger W, Thalhammer F (2017). Micafungin plasma levels are not affected by continuous renal replacement therapy: Experience in critically ill patients. Antimicrob Agents Chemother 61: e02425-16
    • Wulkersdorfer B, Jaros D, Eberl S, Poschner S, Jäger W, Cosentini E, Zeitlinger M, Schwameis R (2017). Human bile reduces antimicrobial activity of selected antibiotics against Enterococcus faecalis and Escherichia coli in vitro. Antimicrob Agents Chemother 61: e00527-17; Q1


    • Bauer M, Römermann K, Karch R, Wulkersdorfer B, Stanek J, Philippe C, Maier-Salamon A, Haslacher H, Jungbauer C, Wadsak W, Jäger W, Löscher W, Hacker M, Zeitlinger M, Langer O. (2016) Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood-Brain Barrier. Clinical Pharmacology & Therapeutics100: 131–141.
    • Ferk F, Mišík M, Nersesyan A, Pichler C, Jäger W, Szekeres T, Marculescu R, Poulsen HE, Henriksen T, Bono R, Romanazzi V, Al-Serori H, Biendl M, Wagner KH, Kundi M, Knasmüller S (2016) Impact of xanthohumol (a prenylated flavonoid from hops) on DNA stability and other health-related biochemical parameters: Results of human intervention trials. Molecular Nutrition & Food Research 60: 773–786.
    • Holzner S, Senfter D, Stadler S, Staribacher A, Nguyen CH, Gaggl A, Geleff S, Huttary N, Krieger S, Jäger W, Dolznig H, Mader RM, Krupitza G (2016) Colorectal cancer cell-derived microRNA200 modulates the resistance of adjacent blood endothelial barriers in vitro. Oncology reports 36: 3065–3071.
    • Klaus R, Jin C, Maier-Salamon A, Jäger W, Knopf C, Zeitlinger M, Richter-Müksch S, Schmidl D, Schmetterer L, Garhöfer G (2016) An Exploratory Microdialysis Study to Assess the Ocular Pharmacokinetics of Ciprofloxacin Eye Drops in Rabbits. Journal of Ocular Pharmacology and Therapeutics 32: 390–395.
    • Kucinska M, Piotrowska-Kempisty H, Lisiak N, Kaczmarek M, Dams-Kozlowska H, Granig WH, Höferl M, Jäger W, Zehl M, Murias M, Erker T. (2016) Selective anticancer activity of the novel thiobenzanilide 63T against human lung adenocarcinoma cells. Toxicology In Vitro 37: 148–161.
    • Nguyen CH, Brenner S, Huttary N, Li Y, Atanasov AG, Dirsch VM, Holzner S, Stadler S, Riha J, Krieger S, Milovanovic D, Fristiohardy A, Simonitsch-Klupp I, Dolznig H, Saiko P, Szekeres T, Giessrigl B, Jäger W, Krupitza G (2016a) 12(S)-HETE increases intracellular Ca2+ in lymph-endothelial cells disrupting their barrier function in vitro; stabilization by clinical drugs impairing calcium supply. Cancer Letters 380: 174–183.
    • Nguyen CH, Brenner S, Huttary N, Atanasov AG, Dirsch VM, Chatuphonprasert W, Holzner S, Stadler S, Riha J, Krieger S, de Martin R, Bago-Horvath Z, Krupitza G, Jäger W (2016b) AHR/CYP1A1 interplay triggers lymphatic barrier breaching in breast cancer spheroids by inducing 12(S)-HETE synthesis. Human molecular genetics.
    • Nguyen CH, Stadler S, Brenner S, Huttary N, Krieger S, Jaeger W, Dolznig H, Krupitza G (2016c) Cancer cell-derived 12(S)-HETE signals via 12-HETE receptor, RHO, ROCK and MLC2 to induce lymph endothelial barrier breaching. British Journal of Cancer 115: 364–370.
    • Stieger B, Mahdi ZM, Jager W (2016) Intestinal and Hepatocellular Transporters: Therapeutic Effects and Drug Interactions of Herbal Supplements. Annual Review of Pharmacology and Toxicology: Ahead of Print.
    • Vossen MG, Wenisch JM, Maier-Salamon A, Fritsch A, Saria K, Zuba C, Jilch S, Lemmerer R, Unger M, Jaehde U, Jäger W, Thalhammer F (2016) Doripenem treatment during continuous renal replacement therapy. Antimicrobial Agents and Chemotherapy 60: 1687–1694.


    • Andreas M, Zeitlinger M, Wisser W, Jaeger W, Maier-Salamon A, Thalhammer F, Kocher A, Hiesmayr J-M, Laufer G, Hutschala D (2015) Cefazolin and linezolid penetration into sternal cancellous bone during coronary artery bypass grafting. European Journal of Cardio-Thoracic Surgery 48: 758–764.
    • Bauer M, Karch R, Zeitlinger M, Philippe C, Römermann K, Stanek J, Maier-Salamon A, Wadsak W, Jäger W, Hacker M, Müller M, Langer O (2015) Approaching complete inhibition of P-glycoprotein at the human blood-brain barrier: an (R)-[11C]verapamil PET study. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism 35: 743–746.
    • Blaschke M, McKinnon R, Nguyen CH, Holzner S, Zehl M, Atanasov AG, Schelch K, Krieger S, Diaz R, Frisch R, Feistel B, Jäger W, Ecker GF, Dirsch VM, Grusch M, Zupko I, Urban E, … Krupitza G (2015) A eudesmane-type sesquiterpene isolated from Pluchea odorata (L.) Cass. combats three hallmarks of cancer cells: Unrestricted proliferation, escape from apoptosis and early metastatic outgrowth in vitro. Mutation Research 777: 79–90.
    • Brenner S, Klameth L, Riha J, Schölm M, Hamilton G, Bajna E, Ausch C, Reiner A, Jäger W, Thalhammer T, Buxhofer-Ausch V (2015) Specific expression of OATPs in primary small cell lung cancer (SCLC) cells as novel biomarkers for diagnosis and therapy. Cancer Letters 356: 517–524.
    • Brenner S, Riha J, Giessrigl B, Thalhammer T, Grusch M, Krupitza G, Stieger B, Jäger W (2015) The effect of organic anion-transporting polypeptides 1B1, 1B3 and 2B1 on the antitumor activity of flavopiridol in breast cancer cells. International Journal of Oncology 46: 324–332.
    • Crevenna R, Burian A, Oesterreicher Z, Lackner E, Jäger W, Reznicek G, Keilani M, Zeitlinger M (2015) Iontophoresis driven concentrations of topically administered diclofenac in skeletal muscle and blood of healthy subjects. European Journal of Clinical Pharmacology. doi: 10.1007/s00228-015-1909-9.
    • Foster BC, Cvijovic K, Boon HS, Tam TW, Liu R, Murty M, Vu D, Jaeger W, Tsuyuki RT, Barnes J, Vohra S (2015) Melatonin Interaction Resulting in Severe Sedation. Journal of Pharmacy & Pharmaceutical Sciences 18: 124–131.
    • Garhofer G, Klaus R, Maier-Salamon A, Jaeger W, Zeitlinger M, Richter-Mueksch S, Schmetterer L (2015) An exploratory microdialysis study to assess the ocular pharmacokinetics of ciprofloxacin eye drops in rabbits. Investigative Ophthalmology & Visual Science 56:
    • Han Y-S, Quashie PK, Mesplède T, Xu H, Quan Y, Jaeger W, Szekeres T, Wainberg MA (2015) A resveratrol analog termed 3,3’,4,4’,5,5’-hexahydroxy-trans-stilbene is a potent HIV-1 inhibitor. Journal of Medical Virology. doi: 10.1002/jmv.24271.
    • Kaserer T, Höferl M, Müller K, Elmer S, Ganzera M, Jäger W, Schuster D (2015) In Silico Predictions of Drug–Drug Interactions Caused by CYP1A2, 2C9 and 3A4 Inhibition–a Comparative Study of Virtual Screening Performance. Molecular Informatics 34: 431–457.
    • Kiss I, Unger C, Huu CN, Atanasov AG, Kramer N, Chatruphonprasert W, Brenner S, McKinnon R, Peschel A, Vasas A, Lajter I, Kain R, Saiko P, Szekeres T, Kenner L, Hassler MR, Diaz R, … Krupitza G (2015) Lobatin B inhibits NPM/ALK and NF-κB attenuating anaplastic-large-cell-lymphomagenesis and lymphendothelial tumour intravasation. Cancer Letters 356: 994–1006.
    • Kotsampasakou E, Brenner S, Jaeger W, Ecker GF (2015) Identification of Novel Inhibitors of Organic Anion Transporting Polypeptides 1B1 and 1B3 (OATP1B1 and OATP1B3) Using a Consensus Vote of Six Classification Models. Molecular Pharmaceutics 12: 4395–4404.
    • Nguyen CH, Senfter D, Basilio J, Holzner S, Stadler S, Krieger S, Huttary N, Milovanovic D, Viola K, Simonitsch-Klupp I, Jäger W, de Martin R, Krupitza G (2015) NF-κB contributes to MMP1 expression in breast cancer spheroids causing paracrine PAR1 activation and disintegrations in the lymph endothelial barrier in vitro. Oncotarget 6: 39262–39275.
    • Paulitschke V, Berger W, Paulitschke P, Hofstätter E, Knapp B, Dingelmaier-Hovorka R, Födinger D, Jäger W, Szekeres T, Meshcheryakova A, Bileck A, Pirker C, Pehamberger H, Gerner C, Kunstfeld R (2015) Vemurafenib resistance signature by proteome analysis offers new strategies and rational therapeutic concepts. Molecular Cancer Therapeutics 14: 757–768.
    • Riha J, Brenner S, Srovnalova A, Klameth L, Dvorak Z, Jäger W, Thalhammer T (2015) Effects of anthocyans on the expression of organic anion transporting polypeptides (SLCOs/OATPs) in primary human hepatocytes. Food & Function 6: 772–779.
    • Rogojanu R, Thalhammer T, Thiem U, Heindl A, Mesteri I, Seewald A, Jager W, Smochina C, Ellinger I, Bises G (2015) Quantitative Image Analysis of Epithelial and Stromal Area in Histological Sections of Colorectal Cancer: An Emerging Diagnostic Tool. BioMed research international 2015: 569071–569071.
    • Saiko P, Steinmann M-T, Schuster H, Graser G, Bressler S, Giessrigl B, Lackner A, Grusch M, Krupitza G, Bago-Horvath Z, Jaeger W, Fritzer-Szekeres M, Szekeres T (2015) Epigallocatechin gallate, ellagic acid, and rosmarinic acid perturb dNTP pools and inhibit de novo DNA synthesis and proliferation of human HL-60 promyelocytic leukemia cells: Synergism with arabinofuranosylcytosine. Phytomedicine 22: 213–222.
    • Schmidt E, Ryabchenko B, Wanner J, Jäger W, Jirovetz L (2015) Cytotoxic active constituents of essential oils of Curcuma longa and Curcuma zanthorrhiza. Natural Product Communications 10: 139–141.
    • Senfter D, Holzner S, Kalipciyan M, Staribacher A, Walzl A, Huttary N, Krieger S, Brenner S, Jäger W, Krupitza G, Dolznig H, Mader RM (2015) Loss of miR-200 family in 5-fluorouracil resistant colon cancer drives lymphendothelial invasiveness in vitro. Human Molecular Genetics 24: 3689–3698.
    • Unger C, Kiss I, Vasas A, Lajter I, Kramer N, Atanasov AG, Nguyen CH, Chatuphonprasert W, Brenner S, Krieger S, McKinnon R, Peschel A, Kain R, Saiko P, Szekeres T, Kenner L, Hassler MR, … Krupitza G (2015) The germacranolide sesquiterpene lactone neurolenin B of the medicinal plant Neurolaena lobata (L.) R.Br. ex Cass inhibits NPM/ALK-driven cell expansion and NF-κB-driven tumour intravasation. Phytomedicine 22: 862–874.
    • Zupkó I, Jaeger W, Topcu Z, Wu C-C (2015) Anticancer Properties of Natural Products. BioMed Research International 2015: 242070.


    • Groessl M, Slany A, Bileck A, Gloessmann K, Kreutz D, Jaeger W, Pfeiler G, Gerner C (2014) Proteome profiling of breast cancer biopsies reveals a wound healing signature of cancer-associated fibroblasts. Journal of proteome research 13(11): 4773-82
    • Hintersteiner J, Haider M, Luger D, Schwarzer C, Reznicek G, Jaeger W, Khom S, Mihovilovic MD, Hering S (2014) Esters of valerenic acid as potential prodrugs. European Journal of Pharmacology 735: 123-131
    • Horvatits T, Kitzberger R, Drolz A, Zauner C, Jaeger W, Boehmdorfer M, Kraff S, Fritsch A, Thalhammer F, Fuhrmann V, Schenk P (2014) Pharmacokinetics of Ganciclovir during Continuous Venovenous Hemodiafiltration in Critically Ill Patients. Antimicrobial Agents and Chemotherapy 58(1): 94-101
    • Kalayda GV, Michaelis M, Cinatl J, Jr., Mader RM, Froehlich H, Sarin N, Melin J, Engel F, Jaeger W, Froetschl R, Jaehde U, Kloft C, Ritter CA (2014) A systems pharmacology approach to improve drug therapy in NSCLC: Establishing a CESAR network. International Journal of Clinical Pharmacology and Therapeutics 52(1): 89-91
    • Kiskova T, Jendzelovsky R, Rentsen E, Maier-Salamon A, Kokosova N, Papcova Z, Mikes J, Orendas P, Bojkova B, Kubatka P, Svoboda M, Kajo K, Fedorocko P, Jaeger W, Ekmekcioglu C, Kassayova M, Thalhammer T (2014) Resveratrol enhances the chemopreventive effect of celecoxib in chemically induced breast cancer in rats. European Journal of Cancer Prevention 23(6): 506-513
    • Kucinska M, Piotrowska H, Luczak MW, Mikula-Pietrasik J, Ksiazek K, Wozniak M, Wierzchowski M, Dudka J, Jaeger W, Murias M (2014) Effects of hydroxylated resveratrol analogs on oxidative stress and cancer cells death in human acute T cell leukemia cell line Prooxidative potential of hydroxylated resveratrol analogs. Chemico-Biological Interactions 209: 96-110
    • Mader RM, Foerster S, Sarin N, Michaelis M, Cinatl J, Jr., Kloft C, Froehlich H, Engel F, Kalayda GV, Jaeger W, Froetschl R, Jaehde U, Ritter CA (2014) NSCLC cells adapted to EGFR inhibition accumulate EGFR interacting proteins and down-regulate microRNA related to epithelial-mesenchymal transition. International Journal of Clinical Pharmacology and Therapeutics 52(1): 92-94
    • Maier-Salamon A, Thalhammer T, Reznicek G, Boehmdorfer M, Zupko I, Hartl A, Jaeger W (2014) Cytochrome P450 3A-mediated metabolism of the topoisomerase I inhibitor 9-aminocamptothecin: Impact on cancer therapy. International Journal of Oncology 45(2): 877-886
    • Peyrl A, Sauermann R, Chocholous M, Azizi AA, Jaeger W, Hoeferl M, Slavc I (2014) Pharmacokinetics and Toxicity of Intrathecal Liposomal Cytarabine in Children and Adolescents Following Age-Adapted Dosing. Clinical Pharmacokinetics 53(2): 165-173
    • Riha J, Brenner S, Boehmdorfer M, Giessrigl B, Pignitter M, Schueller K, Thalhammer T, Stieger B, Somoza V, Szekeres T, Jaeger W (2014a) Resveratrol and its major sulfated conjugates are substrates of organic anion transporting polypeptides (OATPs): Impact on growth of ZR-75-1 breast cancer cells. Molecular Nutrition & Food Research 58(9): 1830-1842
    • Secky L, Svoboda M, Klameth L, Bajna E, Hamilton G, Zeillinger R, Jager W, Thalhammer T (2013) The sulfatase pathway for estrogen formation: targets for the treatment and diagnosis of hormone-associated tumors. Journal of drug delivery 2013: 957605-957605
    • Teichmann M, Kretschy N, Kopf S, Jarukamjorn K, Atanasov AG, Viola K, Giessrigl B, Saiko P, Szekeres T, Mikulits W, Dirsch VM, Huttary N, Krieger S, Jaeger W, Grusch M, Dolznig H, Krupitza G (2014) Inhibition of tumour spheroid-induced prometastatic intravasation gates in the lymph endothelial cell barrier by carbamazepine: drug testing in a 3D model. Archives of Toxicology 88(3): 691-699
    • Vossen MG, Gattringer K-B, Jaeger W, Kraff S, Thalhammer F (2014) Single-Dose Pharmacokinetics of Cidofovir in Continuous Venovenous Hemofiltration. Antimicrobial Agents and Chemotherapy 58(4): 1952-1955


    • Andreas M.; Zeitlinger M.; Hoeferl M.; Jaeger W.; Zimpfer D.; Hiesmayr J.-M.; Laufer G.; Hutschala D. Internal mammary artery harvesting influences antibiotic penetration into presternal tissue. The Annals of thoracic surgery (2013), 95(4), 1323-30
    • Bauer M.; Karch R.; Zeitlinger M.; Stanek J.; Philippe C.; Wadsak W.; Mitterhauser M.; Jager W.; Haslacher H.; Muller M.; et al.  Interaction of 11C-Tariquidar and 11C-Elacridar with P-Glycoprotein and Breast Cancer Resistance Protein at the Human Blood-Brain Barrier. Journal of nuclear medicine (2013), 54(8), 1181-7Bauer, M.; Zeitlinger, M.; Todorut, D.; Boehmdorfer, M.; Mueller, M.; Langer, O.; Jaeger, W. Pharmacokinetics of Single Ascending Doses of the P-Glycoprotein Inhibitor Tariquidar in Healthy Subjects. Pharmacology (2013), 91(1-2), 12-19.
    • Buxhofer-Ausch, V.; Secky, L.; Wlcek, K.; Svoboda, M.; Kounnis, V.; Briasoulis, E.; Tzakos, A. G.; Jaeger, W.; Thalhammer, T. Tumor-specific expression of organic anion-transporting polypeptides: transporters as novel targets for cancer therapy. Journal of Drug Delivery (2013), 863539
    • Hutschala, D.; Skhirtladze, K.; Kinstner, C.; Zeitlinger, M.; Wisser, W.; Jaeger, W.; Hoeferl, M.; Mueller, M.; Tschernko, E. Effect of cardiopulmonary bypass on regional antibiotic penetration into lung tissue. Antimicrobial Agents and Chemotherapy (2013), 57(7), 2996-3002.
    • Kopf S.; Viola K.; Atanasov A. G.; Jarukamjorn K.; Rarova L.; Kretschy N.; Teichmann M.; Vonach C.; Saiko P.; Giessrigl B.; et al. In vitro characterisation of the anti-intravasative properties of the marine product heteronemin. Archives of toxicology (2013)
    • Kretschy, N.; Teichmann, M.; Kopf, S.; Atanasov, A. G.; Saiko, P.; Vonach, C.; Viola, K.; Giessrigl, B.; Huttary, N.; Raab, I.; et al. In vitro inhibition of breast cancer spheroid-induced lymphendothelial defects resembling intravasation into the lymphatic vasculature by acetohexamide, isoxsuprine, nifedipin and proadifen. British Journal of Cancer (2013), 108(3), 570-578.
    • Maier-Salamon A.; Bohmdorfer M.; Riha J.; Thalhammer T.; Szekeres T.; Jaeger W.. Interplay between metabolism and transport of resveratrol Annals of the New York Academy of Sciences (2013), 1290(1), 98-106
    • Roth, G. A.; Sipos, W.; Hoeferl, M.; Boehmdorfer, M.; Schmidt, E. M.; Hetz, H.; Schebesta, K.; Klaus, D.; Motal, M.; Jaeger, W.; et al. The effect of the molecular adsorbent recirculating system on moxifloxacin and meropenem plasma levels. Acta Anaesthesiologica Scandinavica (2013), 57(4), 461-467.
    • Saiko P.; Graser G.; Giessrigl B.; Steinmann M.-T.; Schuster H.; Lackner A.; Grusch M.; Krupitza G.; Jaeger W.; Somepalli V.; et al Digalloylresveratrol, a novel resveratrol analog inhibits the growth of human pancreatic cancer cells Investigational new drugs (2013)
    • Sauermann, R.; Burian, B.; Burian, Angela; Jaeger, Walter; Hoeferl, Martina; Stella, Alexander; Theurer, Stefanie; Riedl, Michaela; Zeitlinger, Markus. Tissue pharmacokinetics of ertapenem at steady-state in diabetic patients with leg infections Journal of Antimicrobial Chemotherapy (2013), 68(4), 895-899
    • Secky, Lena; Svoboda, Martin; Klameth, Lukas; Bajna, Erika; Hamilton, Gerhard; Zeillinger, Robert; Jaeger, Walter; Thalhammer, Theresia.  The sulfatase pathway for estrogen formation: targets for the treatment and diagnosis of hormone-associated tumors. Journal of Drug Delivery (2013), 957605, 13 pp
    • Vareli Katerina; Jaeger Walter; Touka Anastasia; Frillingos Stathis; Briasoulis Evangelos; Sainis Ioannis. Hepatotoxic Seafood Poisoning (HSP) Due to Microcystins: A Threat from the Ocean? Marine drugs (2013), 11(8), 2751-68
    • Viola, K.; Kopf, S.; Huttary, N.; Vonach, C.; Kretschy, N.; Teichmann, M.; Giessrigl, B.; Raab, I.; Stary, S.; Krieger, S.; et al . Bay11-7082 inhibits the disintegration of the lymphendothelial barrier triggered by MCF-7 breast cancer spheroids; the role of ICAM-1 and adhesion. British Journal of Cancer (2013), 108(3), 564-569.
    • Viola, Katharina; Kopf, Sabine; Rarova, Lucie; Jarukamjorn, Kanokwan; Kretschy, Nicole; Teichmann, Mathias; Vonach, Caroline; Atanasov, Atanas G.; Giessrigl, Benedikt; Huttary, Nicole; et al. Xanthohumol attenuates tumour cell-mediated breaching of the lymphendothelial barrier and prevents intravasation and metastasis. Archives of Toxicology (2013), 87(7), 1301-1312.


    • Bauer, M., Zeitlinger, M., Karch, R., Matzneller, P., Stanek, J., Jäger, W., Böhmdorfer, M., Wadsak, W., Mitterhauser, M., Bankstahl, J.P., Löscher, W., Köpp, M., Kuntner, C., Müller, M., Langer, O. (2012) Pgp-mediated interaction between (R)-[C-11]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data. Clinical Pharmacology & Therapeutics 91:227-233
    • Giessrigl, B., Krieger, S., Rosner, M., Huttary, N., Saiko, P., Alami, M., Messaoudi, S., Peyrat, J.-F., Maciuk, A., Gollinger, M., Kopf S., Kazlauskas, E., Mazal, P., Szekeres, T., Hengstschläger, M., Matulis, D., Jäger, W., Krupitza, G. (2012) Hsp90 stabilizes Cdc25A and counteracts heat shock-mediated Cdc25A degradation and cell-cycle attenuation in pancreatic carcinoma cells. Human Molecular Genetics 21:4615-4627
    • Giessrigl, B., Yazici, G., Teichmann, M., Kopf, S., Ghassemi, S., Atanasov, A.G., Dirsch, V.M., Grusch, M., Jäger, W., Ozmen, A., Krupitza, G. (2012) Effects of Scrophularia extracts on tumor cell proliferation, death and intravasation through lymphoendothelial cell barriers. International Journal of Oncology 40:2063-2074
    • Jäger, W., Xu, H., Wlcek, K., Schüler, C., Rubel, F., Erben, R.G. (2012) Gender- and dose-related effects of cyclosporin A on hepatic and bone metabolism. Bone 50:140-148
    • Kiskova, T., Ekmekcioglu, C., Garajova, M., Orendas, P., Bojkova, B., Bobrov, N., Jäger, W., Kassayova, M., Thalhammer, T. (2012) A combination of resveratrol and melatonin exerts chemopreventive effects in N-methyl-N-nitrosourea-induced rat mammary carcinogenesis. European Journal of Cancer Prevention 21:163-170
    • Rotches-Ribalta, M., Urpi-Sarda, M., Llorach, R., Boto-Ordonez, M., Jauregui, O., Chiva-Blanch, G., Perez-Garcia, L., Jäger, W., Guillen, M., Corella, D., Tinahones, F.J., Estruch, R., Andres-Lacueva, C. (2012) Gut and microbial resveratrol metabolite profiling after moderate long-term consumption of red wine versus dealcoholized red wine in humans by an optimized ultra-high-pressure liquid chromatography tandem mass spectrometry method. Journal of Chromatography A 1265:105-113
    • Rützler, K., Sima, B., Mayer, L., Golescu, A., Dunkler, D., Jäger, W., Höferl, M., You, J., Sessler, D.I., Grubhofer, G., Hutschala, D. (2012) Lidocaine/tetracaine patch (Rapydan) for topical anaesthesia before arterial access: a double-blind, randomized trial. British Journal of Anaesthesia 109:790-796
    • Sauermann, R., Feurstein, T., Karch, R., Kjellsson, M.C., Jäger, W., Böhmdorfer, M., Püspök, A., Langenberger, H., Wild, T., Winkler, S., Zeitlinger, M. (2012) Abscess penetration of cefpirome: concentrations and simulated pharmacokinetic profiles in pus. European Journal of Clinical Pharmacology 68:1419-1423
    • Sauermann, R., Karch, R., Kjellsson, M.C., Feurstein, T., Püspök, A., Langenberger, H., Böhmdorfer, M., Jäger, W., Zeitlinger, M. (2012) Good penetration of moxifloxacin into human abscesses. Pharmacology 90:146-150
    • Seelinger, M., Popescu, R., Giessrigl, B., Jarukamjorn, K., Unger, C., Wallnöfer, B., Fritzer-Szekeres, M., Szekeres, T., Diaz, R., Jäger, W., Frisch, R., Kopp, B., Krupitza, G. (2012) Methanol extract of the ethnopharmaceutical remedy Smilax spinosa exhibits anti-neoplastic activity. International Journal of Oncology 41:1164-1172
    • Tobudic, S., Matzneller, P., Stoiser, B., Wenisch, J.M., Zeitlinger, M., Vychytil, A., Jäger, W., Böhmdorfer, M., Reznicek, G., Burgmann, H. (2012) Pharmacokinetics of intraperitoneal and intravenous fosfomycin in automated peritoneal dialysis patients without peritonitis. Antimicrobial Agents and Chemotherapy 56:3992-3995
    • Vohra, S., Cvijovic, K., Boon, H., Foster, B.C., Jäger, W., LeGatt, D., Cembrowski, G., Murty, M., Tsuyuki, R.T., Barnes, J., Charrois, T.L., Arnason, J.T., Necyk, C., Ware, M., Rosychuk, R.J. (2012) Study of Natural Health Product Adverse Reactions (SONAR): Active Surveillance of Adverse Events Following Concurrent Natural Health Product and Prescription Drug Use in Community Pharmacies. Plos One 7: e45196


    • Böhmdorfer M, Maier-Salamon A, Taferner B, Reznicek G, Thalhammer T, Hering S, Hüfner A, Schühly W, Jäger W. In vitro metabolism and disposition of honokiol in rat and human livers. J. Pharm. Sci. 100:3506-16 (2011).
    • Burian A, Wagner C, Stanek J, Manafi M, Böhmdorfer M, Jäger W, Zeitlinger M. Plasma protein binding may reduce antimicrobial activity by preventing intra-bacterial uptake of antibiotics, for example clindamycin. J. Antimicrob. Chemother. 66:134-7 (2011).
    • Cvijovic, K., Boon, H., Jaeger, W. and Vohra, S. (2011) Polypharmacy, multiple natural health products and hepatotoxicity. Canadian Medical Association Journal, 183, E1085-1089.
    • Ferk F, Chakraborty A, Jäger W, Kundi M, Bichler J, Mišík M, Wagner KH, Grasl-Kraupp B, Sagmeister S, Haidinger G, Hoelzl C, Nersesyan A, Dušinská M, Simić T, Knasmüller S.: Potent protection of gallic acid against DNA oxidation: results of human and animal experiments. Mutation Research, Fundamental and Molecular Mechanisms of Mutagenesis, 715, 61-71.
    • Jäger W, Gruber A, Giessrigl B, Krupitza G, Szekeres T, Sonntag D. Metabolomic analysis of resveratrol-induced effects in the human breast cancer cell lines MCF-7 and MDA-MB-231. OMICS 15:9-14 (2011).
    • Leitner JM, Meyer B, Fuhrmann V, Saria K, Zuba C, Jäger W, Böhmdorfer M, Thalhammer F. Multiple-dose pharmacokinetics of anidulafungin during continuous venovenous haemofiltration. J. Antimicrob. Chemother. 66:880-4 (2011).
    • Maier-Salamon A, Böhmdorfer M, Thalhammer T, Szekeres T, Jaeger W. Hepatic glucuronidation of resveratrol: interspecies comparison of enzyme kinetic profiles in human, mouse, rat, and dog. Drug. Metab. Pharmacokinet. 26:364-73 (2011).
    • Rögelsperger O, Wlcek K, Ekmekcioglu C, Humpeler S, Svoboda M, Königsberg R, Klimpfinger M, Jäger W, Thalhammer T. Melatonin receptors, melatonin metabolizing enzymes and cyclin D1 in human breast cancer. J. Recept. Signal Transduct. Res. 31:180-7 (2011).
    • Ryabchenko, B., Tulupova, E., Schmidt, E., Jäger, W., Buchbauer, G., Jirovetz, L. (2011) Cytotoxic Properties of Selected Sesquiterpene Alcohols on Human Cervix Carcinoma Cell Lines. Journal of Essential Oil-Bearing Plants, 14, 316-319.
    • Saiko P, Graser G, Giessrigl B, Lackner A, Grusch M, Krupitza G, Basu A, Sinha BN, Jayaprakash V, Jaeger W, Fritzer-Szekeres M, Szekeres T. A novel N-hydroxy-N'-aminoguanidine derivative inhibits ribonucleotide reductase activity: Effects in human HL-60 promyelocytic leukemia cells and synergism with arabinofuranosylcytosine (Ara-C). Biochem. Pharmacol. 81:50-9 (2011).
    • Saiko, P., Graser, G., Madlener, S., Schwarz, S., Krupitza, G., Jaeger, W., Somepalli, V., Golakoti, T., Fritzer-Szekeres, M. and Szekeres, T. (2011) Combination Effects of Digalloylresveratrol With Arabinofuranosylcytosine and Difluorodeoxycytidine in Human Leukemia and Pancreatic Cancer Cells. Nucleosides, Nucleotides & Nucleic Acids, 30, 1190-1196.
    • Schreier, S. M., Steinkellner, H., Jirovetz, L., Hermann, M., Exner, M., Gmeiner, B. M. K., Kapiotis, S. and Laggner, H. (2011) S-Carbamoylation impairs the oxidant scavenging activity of cysteine: Its possible impact on increased LDL modification in uraemia. Biochimie, 93, 772-777.
    • Svoboda M, Riha J, Wlcek K, Jaeger W, Thalhammer T. Organic anion transporting polypeptides (OATPs): regulation of expression and function. Curr. Drug Metab. 12:139-53 (2011).
    • Svoboda M, Wlcek K, Taferner B, Hering S, Stieger B, Tong D, Zeillinger R, Thalhammer T, Jäger W. Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: Relevance for paclitaxel transport. Biomed. Pharmacother. 65, 417-426.
    • Szekeres T, Saiko P, Fritzer-Szekeres M, Djavan B, Jäger W.: Chemopreventive effects of resveratrol and resveratrol derivatives. Ann. N Y Acad. Sci. 1215:89-95 (2011).
    • Tam, T. W., Akhtar, H., Arnason, J. T., Cvijovic, K., Boon, H., Cameron, D. W., Drouin, C. E., Jaeger, W., Tsuyuki, R. T., Vohra, S. and Foster, B. C. (2011) Inhibition of human cytochrome p450 metabolism by blended herbal products and vitamins. Journal of Pharmacy and Pharmceutical Sciences, 14, 1-16.
    •  Vonach C, Viola K, Giessrigl B, Huttary N, Raab I, Kalt R, Krieger S, Vo TP, Madlener S, Bauer S, Marian B, Hämmerle M, Kretschy N, Teichmann M, Hantusch B, Stary S, Unger C, Seelinger M, Eger A, Mader R, Jäger W, Schmidt W, Grusch M, Dolznig H, Mikulits W, Krupitza G. NF-κB mediates the 12(S)-HETE-induced endothelial to mesenchymal transition of lymphendothelial cells during the intravasation of breast carcinoma cells. Br. J Cancer. 105:263-71 (2011).
    • Wlcek K, Svoboda M, Riha J, Zakaria S, Olszewski U, Dvorak Z, Sellner F, Ellinger I, Jäger W, Thalhammer T. The analysis of organic anion transporting polypeptide (OATP) mRNA and protein patterns in primary and metastatic liver cancer. Cancer Biol. Ther. 11:801-11 (2011).


    • Cvijovic K, Boon H, Jaeger W, Vohra S. Pharmacists' participation in research: a case of trying to find the time. Int. J. Pharm. Pract. 18:377-83 (2010).
    • Miksits, M; Wlcek, K; Svoboda, M; Thalhammer, T; Ellinger, I; Stefanzl, G; Falany, CN; Szekeres, T; Jaeger, W. Expression of sulfotransferases and sulfatases in human breast cancer: Impact on resveratrol metabolism. Cancer Lett. 289:237-245 (2010).
    • Miksits, M; Maier-Salamon, A; Thanh, PNV; Sulyok, M; Schuhmacher, R; Szekeres, T; Jäger, W. Glucuronidation of piceatannol by human liver microsomes: major role of UGT1A1, UGT1A8 and UGT1A10. J. Pharm. Pharmacol. 62: 47-54 (2010).Madlener, S; Saiko, P; Vonach, C; Viola, K; Stark, NHN; Popescu, R; Gridling, M; Vo, NTP; Herbacek, I; Davidovits, A; Giessrigl, B; Venkateswarlu, S; Geleff, S; Jäger, W; Grusch, M; Kerjaschki, D; Mikulits, W; Golakoti, T; Fritzer-Szekeres, M; Szekeres, T; Krupitza, G. Multifactorial anticancer effects of digalloyl-resveratrol encompass apoptosis, cell-cycle arrest, and inhibition of lymphendothelial gap formation in vitro. Br. J. Cancer. 102:1361-1370 (2010).
    • Paulitschke, V; Schicher, N; Szekeres, T; Jäger, W; Elbling, L; Riemer, AB; Scheiner, O; Trimurtulu, G; Venkateswarlu, S; Mikula, M; Swoboda, A; Fiebiger, E; Gerner, C; Pehamberger, H; Kunstfeld, R.: 3,3 ',4,4 ',5,5 '-Hexahydroxystilbene Impairs Melanoma Progression in a Metastatic Mouse Model. J. Invest. Dermatol. 130:1668-1679 (2010).
    • Szekeres, T; Fritzer-Szekeres, M; Saiko, P; Jäger, W. 2010. Resveratrol and Resveratrol Analogues-Structure-Activity Relationship. Pharm. Res 27:1042-1048 (2010).
    • Vo, NT; Madlener, S; Bago-Horvath, Z; Herbacek, I; Stark, N; Gridling, M; Probst, P; Giessrigl, B; Bauer, S; Vonach, C; Saiko, P; Grusch, M; Szekeres, T; Fritzer-Szekeres, M; Jäger, W; Krupitza, G; Soleiman, A.:Pro- and anticarcinogenic mechanisms of piceatannol are activated dose dependently in MCF-7 breast cancer cells. Carcinogenesis 31:2074-2081 (2010).


    • Bernhaus A, Fritzer-Szekeres M, Grusch M, Saiko P, Krupitza G, Venkateswarlu S, Trimurtulu G, Jäger W, Szekeres T. Digalloylresveratrol, a new phenolic acid derivative induces apoptosis and cell cycle arrest in human HT-29 colon cancer cells. Cancer Lett. 274: 299-304 (2009).
    • Bernhaus A, Ozsvar-Kozma M, Saiko P, Jaschke M, Lackner A, Grusch Mi, Horvath Z, Madlener S, Krupitza G, Handler N, Erker T, Jäger W, Fritzer-Szekeres M, Szekeres T. Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cells. Invest. New Drugs 27: 393-401 (2009).
    • Dadak AM, Franz S, Jäger W, Tichy A, Baumgartner W, Mosing M.: Pharmacokinetics and clinical efficacy of lidocaine in cattle after intranasal administration during rhinotracheobronchoscopy. J. Vet. Pharmacol. Ther. 32:300-302 (2009).
    • Jäger W. Classical resistance mechanisms. Int. J. Clin. Pharmacol. Ther. 47: 46-8 (2009).
    • Maier-Salamon A, Trauner G, Hiltscher R, Reznicek G, Kopp B, Thalhammer T, Jäger W. Hepatic metabolism and biliary excretion of valerenic acid in isolated perfused rat livers: Role of Mrp2 (Abcc2). J. Pharm. Sci. 98: 3839-3849 (2009). 
    • Miksits M, Sulyok M, Schuhmacher R, Szekeres T, Jäger W. In-vitro sulfation of piceatannol by human liver cytosol and recombinant sulfotransferases. J. Pharm.  Pharmacol. 61: 185-191 (2009).
    • Miksits M, Wlcek K, Svoboda M, Kunert O, Haslinger E, Thalhammer T, Szekeres T, Jäger W. Antitumor activity of resveratrol and its sulfated metabolites against human breast cancer cells. Planta Med. 75: 1227-1230 (2009).
    • Rögelsperger O, Ekmekcioglu C, Jäger W, Klimpfinger M, Königsberg R, Krenbek D, Sellner F, Thalhammer T. Coexpression of the melatonin receptor 1 and nestin in human breast cancer specimens. J. Pineal Res. 46: 422-432 (2009).
    • Saiko P, Ozsvar-Kozma M, Graser G, Lackner A, Grusch M, Madlener S, Krupitza G, Jäger W, Hidvegi M, Agarwal RP, Fritzer-Szekeres M, Szekeres T. Avemar, a nontoxic fermented wheat germ extract, attenuates the growth of sensitive and 5-FdUrd/Ara-C cross-resistant H9 human lymphoma cells through induction of apoptosis. Oncol. Rep. 21: 787-791 (2009).
    • Cvijovic K, Boon H, Barnes J, Brulotte J, Jäger W, Murty M, Vu D, Reid S, Vohra S. A tool for rapid identification of potential herbal medicine-drug interactions. CPJ/RPC 142: 224-227 (2009).
    • Capan M, Keltner S, Thalhammer F, Winkler S, Jäger W, Zeitlinger M, Ramharter M. Intra-cystic drug concentration of albendazole sulphoxide in patients with Echinococcus granulosus cysts. Am. J. Trop. Med. Hyg. 81:712-3 (2009).


    • A. Maier-Salamon, B. Hagenauer, G. Reznicek, T. Szekeres, T. Thalhammer, W. Jäger*. Metabolism and disposition of resveratrol in the isolated perfused rat liver: role of Mrp2 in the biliary excretion of glucuronides. J. Pharm. Sci. 97: 1615-1628 (2008)
    • P. Saiko, A. Szakmary, W. Jaeger, T. Szekeres: Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutation Res. 658: 68-94 (2008)Y. Bader, S. Madlener, S. Strasser, S. Maier, P. Saiko, N. Stark, R. Popescu, D. Huber, M. Gollinger, T. Erker, N. Handler, A. Szakmary, W. Jäger, B. Kopp, I. Tentes, M. Fritzer-Szekeres, G. Krupitza, T. Szekeres: Stibene analogues affect cell cycle progression and apoptosis independently of each other in an MCF-7 array of clones with distinct genetic and chemoresistant backgrounds. Oncol. Rep. 19: 801-810 (2008)
    • M. Murias, M. Miksits, S. Aust, M. Spatzenegger, T. Thalhammer, T. Szekeres, W.Jaeger*: Metabolism of reveratrol in breast cacner cell lines: impact of sulfotransferase 1A1 expression on cell growth inhibition. Cancer Lett. 261: 172-182 (2008)
    • N. Handler, P. Saiko, W. Jaeger, T. Szekeres, V. Wachek, H. Berner, K. Leisser, T. Erker: Synthesis and cytotoxic activity of resveratrol-based compounds. Monatsh. Chem. 139: 575-578 (2008).
    • M. Murias, M.W. Lczak, A. Niepsuj, V. Krajka-Kuzniak, M. Zielinska-Przyjemska, P.P. Jagodzinski, W. Jäger, T. Skekeres, J. Jodynis-Liebert: Cytotoxic activity of 3,3’,4,4’5,5’-hexahydroxystilbene against breast cacner cells is mediated by induction of p53 and downregulation of mitochondrial superoxide dismutase. Toxicol in Vitro 22: 1361-1370 (2008).
    • M. Fritzer-Szekeres, I. Savinc, Z. Horvath, P. Saiko, M. Pemberger, G. Graser, A. Bernhaus, M. Ozsvar-Kozma, M. Grusch, W. Jaeger, T. Szekeres: Biochemical effects of piceatannol inhuman HL-60 promyelocytic leukemia cells-synergism with Ara-C. Int. J. Oncol. 33: 887-892 (2008).
    • P.Saiko, M. Peberger, Z. Horvath, I. Savinc, M. Grusch, N. Handler, T. Erker, W. Jaeger, M. Fritzer-Szekeres, T. Szekeres: Novel resveratrol analogs induce apoptosis and cause cell arrest in HT29 human colon cacner cells: inhibition of ribonucleotide reductase activity. Oncol. Rep. 19: 1621-1626 (2008).
    • R. Königsberg, O. Rögelsperger, W. Jäger, T. Thalhammer, M. Svoboda, M. De Santis, M. Hudec, C. Dittrich: Cell cycle dysregulation influences survival in high risk breast cancer patients. Cancer Invest. 26: 734-740 (2008).
    • S. Aust, W. Jäger, H. Kirschner, M. Klimpfinger, T. Thalhammer: Pancreatic stellate/myofibroblast cells express G-protein-coupled melatonin receptor 1. Wien Med. Wochenschr. 158: 1-4 (2008).
    • K. Wlcek, M. Svoboda, T. Thalhammer, F. Sellner, G. Krupitza, W. Jaeger: Altered expression of organic anion transporter polypeptide (OATP) genes in human breast carcinoma. Cancer Biol. Ther. 7: 1450-5 (2008).
    • L. Gille, W. Stamberg, W. Gregor, W. Jäger, G. Reznicek, T. Netschner, t. Rosenau, H. Nohl: Ubichromanol: a prodrug to support mitochondrial ubiquinone function? Biofactors 32: 83-90 (2008)
    • M. Svoboda, F. Sellner, C. Ekmekcioglu, M. Klimpfinger, W. Jaeger, T. Thalhammer: Expression of estrogen-metabolizing enzymes and estrogen receptors in cholelithiasis gallbladder. Biomed. Pharmacother. 62: 690-6 (2008).
  • Journal Articles 1988 - 2007


    • M. Urpi-Sarda, R. Zamora-Ros, R. Lamuela-Raventos, A. Cherubini, O. Jauregui, R. Torre, M. Covas, R. Estruch, W. Jaeger, C. Anderes-Lacueva: HPLC-tandem mass spectrometric method to characterize resveratrol metabolism in humans. Clin Chem. 53: 292-299 (2007).
    • P. Saiko, M. Ozsvar-Kozma, S. Madlener, A. Bernhaus, A. Lackner, M. Grusch, Z. Horvath, G. Krupitza, W. Jaeger, K. ammer, M. Fritzer-Szekeres, T. Szekeres: Avemar, a nontoxic fermented wheat germ extract, induces apoptosis and inhibits ribonucleotide reductase in human HL-60 promyelocytic leukemia cells. Cancer Lett. 250: 323-8 (2007)
    • L. Gille, W. Stamberg, W. Jäger, G. Reznicek, T. Netscher, T. Rosenau: A new ubiquinone metabolite and its activity at the mitochondrial bc1 complex. Chem Res Toxicol. 20:591-559 (2007)
    • N. Handler, W. Jäger, H. Puschacher, K. Leisser, T. Erker: Synthesis of novel curcumin analogues and their evaluation as selcetive cyclooxygenase-1 (COX-1) inhibitors. Chem. Pharm. Bull. 55: 64-69 (2007).
    • N. Handler, G. Brunhofer, C. Studenik, K. Leiser, W. Jaeger, S. Parth, T. Erker: ‘Bridged’ stilbene derivatives as selective cyclooxygenase-1 inhibitors. Bioorg. Med. Chem. 15: 6109-6118 (2007)
    • Z. Horvath, S. Marihart-Fazekas, P. Saiko, M. Grusch, M. Özsüy, M. Harik, N. Handler, T. Erker, W. Jaeger, M. Fritzer-Szekeres, B. Djavan, T. Szekeres: Novel resveratrol derivatives induce apoptosis and cause cell arrest in prostate cacner cell lines. Anticancer Res. 27: 3459-3464 (2007)
    • V. Fuhrmann, P. Schenk, W. Jaeger, M. Miksits, N. Kneidinger, J. Warszawska, U. Holzinger, R. Kitzberger, F. Thalhammer: Pharmakokinetics of voriconazol during continous venovenous hemodiafiltration, J. Antimicrob. Chemother. 60: 1085-1090 ( 2007).
    • P. Saiko, M. Ozsvar-Kozma, A. Bernhaus, M. Jaschke, G. Graser, A. Lackner, M. Grusch, Z. Horvath, S. Madlener, G. Krupitza, N. Handler, T. Erker, W. Jaeger, M. Fritzer-Szekeres, T. Szekeres: N-hydroxy-N’-(3,4,5-trimethoxyphenyl)-3,4,5-trimethoxy-benzamidine, a novel resveratrol analog, inhibits ribonucleotide reductase in HL-60 human promyelocytic leukemia cells: synergistic antitumor activity with     arabinofuranosylcytosine. Int. J. Oncol. 31: 1261-1266 (2007).


    • P. Saiko; Z. Horvath; M. Murias; N. Handler; W. Jaeger; T. Erker; M. Fritzer-Szekeres, T. Szekeres: Antitumor effects of 3,3’,4,4’,5,5’-hxahydroxystilbene in HL-60 human promyelocytic leukemia cells. Nucleos. Nucleot. Nucl. Acids 25: 1013-1017 (2006).
    • Horvath,.; P. Saiko; C. Illmer; S. Madlener; T. Hoechtl; W. Bauer; T. Erker; W. Jaeger; M. Fritzer-Szekere; T. Szekeres: Resveratrol, an ingredient of wine, acts synergistically with ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells. Nucleos. Nucleot. Nucl. Acids 25: 1019-1024 (2006).
    • R. Zomora-Ros, M. Urpi-Sarda, R. M. Lamuela-Raventos, R. Estruch, M. Vazquez-Agell, M. Serrano-Martinez, W. Jaeger, C. Andres-Lacueva: Diagnostic performance of urine resveratrol metabolites as a biomarker of moderate wine consumption. Clin. Chem. 52: 1773-1780 (2006).
    • Z. Horvath, M. Murias, P. Saiko, T. Erker, N. Handler, W. Jaeger, M. Grusch, M. Fritzer-Szekeres, T. Szekeres: Cytotoxic and biochemical effects of 3, 3’,4,4’,5,5’ hexahydroxystilbene, a novel resveratrol analogue in HL-60 human promyelocytic leukaemia cells. Exp. Hematol. Exp Hematol. 34: 1377-1384 (2006).
    • B. Benedek, N. Geisz, W. Jäger, T. Thalhammer, B. Kopp: Choleretic effects of yarrow (Archillea millefolium s.l.) in the isolated perfused rat liver. Phytomedicine 13: 702-706 (2006).
    • A. Maier-Salamon, B. Hagenauer, M. Wirth, F. Gabor, T. Szekeres, W. Jäger*: Increased transport of resveratrol across monolayers of the human intestinal Caco-2 cells is mediated by inhibition and saturation of metabolites. Pharm. Res. 23: 2107-2115(2006).
    • H. Halbwith, S. Kahl, W. Jäger, G. Reznicek, G. Forkmann, K. Stich: Synthesis of (14C)- labeled 5-deoxyflavonoids and their application in the study of dihydoflavonol/ leucoanthocyanidin interconversion by dihydroflavonol 4-reductase. Plant Sci. 170: 587-595 (2006).


    • Z. Horvath, P. Saiko, C. Illmer, S. Madlener, T. Hoechtl, W. Bauer, T. Erker, W. Jaeger, M. Fritzer-Szekeres, T. Szekeres: Synergistic action of resveratrol, an ingredient of wine,with Ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells. Exp Hematol.33, 329-35 (2005).
    • S. Aust, P. Obrist, M. Klimpfinger, G. Tucek, W. Jäger, T. Thalhammer: Altered expression of the hormone- and xenobiotic-metabolizing sulfotransferase enzymes 1A2and 1C1 in malignant breast tissue. Int. J. Oncol. 26, 1079-85 (2005).
    • M. Murias, W. Jäger*, N. Handler, T. Erker, Z. Horvath, T. Szekeres, H. Nohl, L. Gille: Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues:structure-activity relationship. Biochem. Pharmacol. 69, 903-12 (2005).
    • P. Saiko, Z. Horvath, W. Jaeger, H. Schott, M. Fritzer-Szekeres, T. Szekeres: Heterodinucleoside phosphates of 5-fluorodeoxyuridine and arabinofuranosylcytosine-new drugs in cancer chemotherapy? In Vivo 19, 205-14 (2005).
    • B. Meyer, G.V. Kornek, M. Nikfardjam, G.D. Karth, H.G. Locker, W. Jaeger, F. Thalhammer: Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration. J. Antimicrob. Chemother. 56, 172-9 (2005).
    • P. Saiko, Z. Horvath, C. Illmer, S. Madlener, W. Bauer, T. Hoechtl, N. Erlach, M. Grusch, G. Krupitza, R.M. Mader, W. Jaeger, H. Schott, R.P. Agarwal, M. Fritzer-Szekeres, T. Szekeres: Cytotoxic effects of novel amphiphilic dimers consisting of 5-fluorodeoxyuridine and arabinofuranosylcytosine in cross-resistant H9 human lymphoma cells. Leuk. Res. 29, 785-91 (2005).
    • M. Urpi-Sarda, O. Jauregui, R.M. Lamuela-Raventos, W. Jaeger, M. Miksits, M.I. Covas, C. Andres-Lacueva: Uptake of diet resveratrol into the human low-density lipoprotein. Identification and quantification of resveratrol metabolites by liquid chromatography coupled with tandem mass spectrometry. Anal. Chem. 77: 3149-55 (2005).
    • F. Thalhammer, A. Maier-Salamon, W. Jäger*: Examination of stability and compatibility of flucloxacillin (Floxapen) and ceftazidime (Fortum) in two infusion media: relevance for the clinical praxis. Wien. Med. Wochenschr. 155, 337-43 (2005).
    • G. Buchbauer, . Jäger, A. Gruber, H. Dietrich: R-(+)- and S-(-)-Carvone: influence of chirality on locomotion activity in mice. Flavour Fragr. J. 20, 686-689 (2005).
    • S. Aust, W. Jaeger, M. Klimpfinger, K. Mayer, G. Baravalle, C. Ekmekcioglu, T. Thalhammer: Biotransformation of melatonin in human breast cancer cell lines: Role ofsulfotransferase 1A1. J. Pineal Res. 39, 276-82 (2005).
    • M. Miksits, A. Maier-Salamon, S. Aust, T. Thalhammer, G. Reznicek, O. Kunert, E. Haslinger, T. Szekeres, W. Jaeger*: Sulfation of resveratrol in human liver: evidence of a major role for the sulfotransferases SULT1A1 and SULT1E1. Xenobiotica 35: 1101-1119 (2005).
    • N. Handler, W. Jaeger, B. Kuen-Krismer, T. Erker: Cyclooxygenase-1 and Cyclooxygenase-2 Inhibition of Novel 1,2-Disubtituated Imidazoles. Arch. Pharm. 338: 602-604 (2005).


    • S. Aust, T. Thalhammer, S. Humpeler, W. Jäger, M. Klimpfinger, G. Tucek, P. Obrist, W. Marktl, E. Penner, C. Ekmekcioglu: The melatonin receptor subtype MT1 is expressed in human gallbladder epithelia. J. Pineal Res. 36, 43-48 (2004).
    • M. Murias, N. Handler, T. erker, K. Pleban, G. Ecker, P. Saiko, T. Szekeres, W. Jäger*: Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg. Med. Chem. 12, 5571-5578 (2004).
    • P. Saiko, Z. Horvath, W. Bauer, T. Hoechtl, M. Grusch, G. Kruitza, P. Rauko, R.M. Mader, W. Jäger, H. Schott, L. Novotny, M. Fritzer-Szekeres, T. Szekeres: In vitro and in vivo antitumor activity of novel amphiphilic dimmers consisting of 5-fluorodeoxyuridine and arabinofuranosylcytosine. Int. J. Oncol. 25, 357-364 (2004).
    • P. Friedrich, S. Eappen, W. Jäger, E. Schernhammer, A.M. Zizza, G.K. Wang, P. Gerner: Phase Ia and Ib study of amitryptiline for ulnar nerve block in humans: side effects and efficacy. Anesthesiology 100, 511-518 (2004).
    • V. Fuhrmann, P. Schenk, W. Jäger, S. Ahmed, F. Thalhammer: Pharmacokinetics of moxifloxacin in patients undergoing continous venovenous haemodiafiltration. J. Antimicrob. Chemother. 54, 780-784 (2004).
    • S. Aust, P. Obrist, W. Jäger, M. Klimpfinger, G. Tucek, F. Wrba, E. Penner, T. Thalhammer: Subcellular localization of the ABCG2 transporter in normal and malignant human gallbladder epithelium. Lab Invest. 84, 1024-36 (2004).
    • C. Armbruster, G.M. Stiegler, B.A. Vcelar, W. Jäger, U. Koller, R. Jilch, C.G. Ammann, M. Pruenster, H. Stoiber, H.W. Katinger: Passive immunization with the anti-HIV-1 human monoclonal anibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12. J. Antimicrob. Chemother. 54, 915-920 (2004).
    • B. Hagenauer, A. Maier-Salamon, T. Thalhammer, P. Zollner, A. Senderowicz, W. Jäger*: Metabolism of UCN-01 in isolated perfused rat liver: role of Mrp2 in the biliary excretion of glucuronides. Oncol. Rep. 11: 1069-1075 (2004).


    • W. Jäger*, E. Gehring, B. Hagenauer , S. Aust, A. Senderowicz, T. Thalhammer: Biliary excretion of flavopiridol and ist glucuronides in the isolated perfused rat liver: role of the canalicular multispecific organic anion transporter (cmoat). Life Sci. 73, 2841-2854 (2003).
    • W. Jäger*, E. Gehring, B. Hagenauer, S. Aust, A. Senderowicz, T. Thalhammer: The role of hepatic Mrp2 in the interaction of flavopiridol and bilirubin: impact on therapy. Int. J. Clin. Pharmacol. Ther. 41, 610-611 (2003).
    • W. Weber, W. Jäger, T. Erker: Synthesis of tricyclic pyridol [2,3-b][1,4]-thiazines via nucleophilic substitution of activated precursors. J. Heterocyclic Chem. 40, 851-854 (2003)
    • B. Meyer, S. Gendy, G. Karth, G. Locker, G. Heinz, W. Jäger, F. Thalhammer: How to calculate clearance of highly protein-bound drugs during continuous venovenous hemofiltration demonstrated with flucloxacillin. Kidney Blood Press Res. 26, 135-140 (2003).


    • C. Armbruster, G.M. Stiegler, B.V. Vcelar, W. Jäger, N. Michael, N. Vetter, H.W.D. Katinger: Intravenous therapy with two human monoclonal antibodies (hmAbs 2F5, 2G12) against HIV-1: A phase I trial in asymtomatic volunteers. AIDS 16, 227-233 (2002).
    • R. Gratzl, G. Sodeck, P. Platzer, W. Jäger, J. Graf, A. Pollak, T. Thalhammer: Treatment of toxoplasmosis in pregrancy: concentrations of spiromycin and neospiramycin in maternal serum and amniotic fluid. Eur. J. Clin. Microbiol. Infect. Dis. 21, 12-16 (2002).
    • K. Schaufler, P. Haslmayer, W. Jäger, M. Pec, T. Thalhammer: The environmental toxin 2,3,7,8,-tetrachlorodibenzo-p-dioxin induces cytochrome P450 activity inhigh passage PC 3 and DU 145 human prostate cancer cell lines. Int. J. Mol. Med. 9, 411- 416 (2002)
    • W. Jäger*, A. Salamon, T. Szekeres: Metabolism of the novel IMP dehydrogenase inhibitor benzamide riboside. Curr. Med. Chem. 9, 781-786 (2002).
    • M. Fritzer-Szekeres, A. Salamon, M. Grusch, Z. Horvath, T. Höchtl, R. Steinbrugger, W.Jäger, G. Krupitzka, H. L. Elford, T. Szekeres: Trimidox, an inhibitor of ribonucleotide reductase, synergistically enhances the inhibition of colony formation by Ara-C in HL-60 human promyelocytic leukaemia cells. Biochem. Pharmacol. 64, 481485 (2002).
    • U. Neckel, C. Joukhadar, M. Frossard, W. Jäger, M. Müller, B. X. Mayer. Simultaneous determination of levofloxacin and ciprofloxacin in microdialysates and plasma by high-performance liquid chromatography. Anal. Chim. Acta 463, 199-206 (2002).
    • G. Stiegler, C. Armbruster, B. Vcelar, H. Stoiber, R. Kunert, N. L. Michael, L. L. Lagodzinski, C. Ammann, W. Jäger, J. Jacobson, N. Vetter, H. Kattinger: Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1 infected humans: a phase I eveluation. AIDS 16, 2019-2025 (2002).
    • P. Haslmayer, T. Thalhammer, W. Jäger, S. Aust, G. Steiner, C. Ensinger, P. Obstist: The peroxisome proliferator-activated receptor g ligand 15-deoxy-D12,14-prostaglandin J2 induces vascular endothelial growth factor in the hormone-independent prostate cancer cell line PC 3 and the urinary bladder carcinoma cell line 5637. Int. J. Oncol. 21, 915-920 (2002).


    • W. Jäger*, M. Mayer, U. Kratzert, G. Reznicek, G. Buchbauer: Percutaneous absorption of the monoterpene carvone: implication of stereoselective metabolism on blood levels. J. Pharm. Pharmacol. 53, 637-642 (2001).
    • B. Hagenauer, A. Salamon, T. Thalhammer, O. Kunert, E. Haslinger,P. Klinger, A. M. Senderowicz, E.A. Sausville, W. Jäger*: In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: involvement of UGT1A1 and UGT1A9. Drug. Metab. Disp. 29, 191-197 (2001).
    • T. Bachel, T.Thalhammer, W. Jäger, P. Haslmayer, B. Alihodzic, S. Bakos, E. Hitchman, A.M. Senderowicz, E. Penner: Characterizaion of autoantibodies against uridine-diphosphate glucuronosyltransferase in patients with inflammatory liver diseases. Hepatology 33, 1053-1059 (2001).
    • Salamon, B. Hagenauer, Thalhammer, T. Szekerez, K. Krohn, H.N. Jayaram, W. Jäger*: Metabolism and disposition of the novel antileukaemic drug, benzamide riboside, in the isolated perfused rat liver. Life Sci. 69, 2489-2502 (2001)
    • P. Platzer, T.Thalhammer, G. Reznicek, G. Hamilton, R. Zhang, W. Jäger*: Metabolism and biliary excretion of the novel anticancer agent 10-hydroxycamptothecin in the isolated perfused rat liver. Int. J. Oncol. 19, 1287-1293 (2001).
    • G.F. Fischer, I. Fae, D. Mann, D. Kriks, W. Jäger, W. Platzer, W.R. Mayr, B. Volc-Platzer. An HLA class-II allele frequent in Eskimos and Amerindians is found in the Tyrolean Ice Man. Ann. Hum. Genet. 65, 363-9 (2001),
    • J. Easmon, G. Pürstinger, T. Roth, H.H. Fiebig, M. Jenny, W. Jäger, G. Heinisch, J. Hoffmann: 2-Benzoxazolyl and 2-benzimidazolyl hydrazones derived from 2-acetylpyridine: an novel class of antitumor agents. Int. J. Cancer, 94, 89-96 (2001).
    • J. Easmon, G. Pürstinger, G. Heinisch, T. Roth, H.H. Fiebig, W. Holzer, W. Jäger, M. Jenny, J. Hoffmann: Synthesis, cytotoxicity, and antitumor activity of copper (II) and iron (II) complexes of 4 N-azabicyclo[3.2.2]nonane thiosemicarbazones derived from acyl diazines. J. Med. Chem. 44, 2164-2171 (2001).
    • M. Gaugg, P. Haslmayer, W. Jäger, T.Thalhammer: Influence of hypotonic stress on the biliary excretion of doxorubicin in Wistar and TR-rats. Anticancer. Res. 21, 2745-2752 (2001).


    • P. Platzer, T. Thalhammer, G. Hamilton, E. Ulsberger, E. Rosenberg, R. Wissiack, W. Jäger*: Metabolism of camptothecin, a potent topoisomerase I inhibitor, in the isolated perfused rat liver. Cancer Chemother. Pharmacol. 45, 50-54 (2000).
    • W. Jäger*, M. Mayer, P. Platzer, G. Reznicek, H. Dietrich, G. Buchbauer: Stereoselective metabolism of the monoterpene carvone by rat and human liver microsomes. Pharm. Pharmacol. 52, 191-197 (2000).
    • Hamwi, A. Salamon, R. Steinbrugger, M. Fritzer-Szekeres, W Jaeger, T. Szekeres Cyclosporine metabolism in patients after kidney, bone marrow, heart/lung and liver transplantation in the early and late post-transplant period. Am. J. Clin. Pathol. 114, 536-543 (2000).
    • A. Salamon, E. Vielnascher, B. Hagenauer, T. Szekeres, M. Szekeres-Fritzer, T     Thalhammer, W. Jäger*: Metabolism of the new ribonucleotide reductase inhibitor amidox in the isolated perfused rat liver. Anticancer Res. 20, 3521-3526 (2000).


    • W. Jäger*, M.A. Correia, L.M. Bornheim, A. Mahnke, W.G. Hanstein, L. Xue, L.Z. Benet: Ethynylestradiol-mediated induction of hepatic CYP3A9 in female rats: implication for cyclosporine metabolism. Drug Metab. Dispos. 27, 1505-1511 (1999).


    • K. Jurukamjorn, T. Thalhammer, B. Gollackner, E. Pittenauer, W. Jäger*: Metabolism of roxithromycin in the isolated perfused rat liver. J. Pharm. Pharmacol. 50, 515-519 (1998).
    • W. Jäger*, B. Zembsch, P. Wolschann, E. Pittenauer, A.M. Senderowicz, E.A. Sausville, H.H. Selacek, J. Graf, T. Thalhammer: Metabolism of the new anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver. Life Sci. 62, 1861-1873 (1998).
    • P. Platzer, S. Schaden, T. Thalhammer, G. Hamilton, W. Jäger*: Biotransformation of     topotecan in isolated perfused rat liver: identification of three novel metabolites.     Anticancer Res. 18, 2695-2700 (1998).
    • P. Platzer, W. Herzog, T. Thalhammer, G. Hamilton, I. Haberl, W. Jäger*: Formation of a novel topotecan metabolite in the hormone-independent human prostate carcinoma cell lines DU-145 and PC-3. Anticancer Res. 18, 2737-2742 (1998).
    • W. Jäger*, M. Sartori, W. Herzog, T. Thalhammer: Genistein metabolism in liver microsomes of Wistar and mutant TR--rats. Res. Commun. Mol. Path. 100, 105-116 (1998).
    • M. Spatzenegger, G. Ecker, W. Jäger*: Metabolism of the new MDR-modifier AM05 by human liver microsomes. Sci. Pharm. 66, 159-168 (1998).


    • E. Vielnascher, D. Romanova, L. Novotny, T. Szekeres, H.L. Elfort, T. Thalhammer, W. Jäger*: Simultaneous determination of the new anticancer agent amidox and its metabolites in rat bile and plasma by high-performance liquid chromatography. J. Chromatogr. B 696, 267-274 (1997).
    • W. Jäger*, O. Winter, B. Halper, A. Salamon, M. Sartori, L. Gajdzik, G. Hamilton, G. Theyer, J. Graf, T.Thalhammer: Modulation of liver canalicular transport processes by the tyrosin-kinase inhibitor genistein: implication of genistein metabolism. Hepatology 26, 1467-1476 (1997).
    • P. Chiba, B. Tell, W. Jäger, E. Richter, M. Hitzler, G. Ecker: Studies on propafenon-type modulators of multidrug-resistance IV: synthesis and pharmacological activity of 5-hydroxy and 5-benzyloxy derivatives. Arch. Pharm. Med. Chem. 330, 343-347 (1997).
    • N. Fuchs, W. Jäger, A. Lenhardt, L. Böhm, I. Buchbauer, G. Buchbauer: Systemic absorption of topically applied carvone: Influence of massage technique. J. Soc. Cosmet. Chem. 48, 277-282 (1997).


    • W. Jaeger, L.Z. Benet, L.M. Bornheim*: Inhibition of cyclosporine and tetrahydro-cannabinol metabolism by cannabidiol in mouse and human microsomes. Xenobiotica 26, 275-284 (1996).
    • G. Finding, R. Madner, M. Fritzer-Szekeres, G. G. Steger, W. Jäger, T. Szekeres: Modulation of 5-fluorouracil resistance in human colon tumor cell lines by azidothymidine. Oncol. Res. 8, 189-196 (1996).
    • M. Spatzenegger, G. Ecker, W. Jäger*: Determination of the new MDR-modifier PFP 6 and its metabolites in human liver microsomes by high-performance liquid chromatography. Biomed. Chromatogr. 10, 127-130 (1996).
    • E. Vielnascher, M. Spatzenegger, A. Mayrhofer, P. Klinger W. Jäger*: Metabolism of dextromethorphan in human liver microsomes: a rapid HPLC assay to monitor cytochrome P450 2D6 activity. Pharmazie 51, 586-588 (1996).
    • W. Jäger*, E. Vielnascher, G. Findenig, R.M. Mader, T. Szekeres: Effect of 3'-azido-3'-deoxythymidine on 5-fluorouracil metabolism in human promyelocytic leukaemia HL-60 cells. Pharm. Sci. 2, 445-447 (1996).
    • G. Finding, R. Madner, M. Fritzer-Szekeres, G. G. Steger, W. Jäger, T. Szekeres: Modulation of 5-fluorouracil resistance in human colon tumor cell lines by azidothymidine. Oncol. Res. 8, 189-196 (1996).
    • W. Jäger*, B. Nasel, C. Nasel, R. Binder, T. Stimpfl. W. Vycudilik: Pharmacokinetic studies of the fragrance compound 1,8-cineol in humans during inhalation. Chem. Senses 21, 477-480 (1996).


    • W. Jäger*, B. Päsler, G. Buchbauer, P. Chiba: Investigation of cytotoxic effects of 8 norbornane derivatives on 4 human cancer cell lines using the MTT assay. Pharmazie, 50, 619-621 (1995).
    • M. Spatzenegger, W. Jäger*: Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug. Metab. Rev. 27, 397-417 (1995).


    • L. Jirovetz, H.P. Koch, W. Jäger, G. Fritz, G. Resl: Purslane (Portulaca oleracea L.): Investigation of the plant constituents by means of chromatographic spectroscopic systems for the control of the described cholesterol reduction. Ernährung/Nutrition l7, 226-227 (1993).
    • M. Czejka, W. Jäger, J. Schüller, U. Fogl, C. Weiss, G. Schernthaner: Clinical pharmacokinetics and bioavailability of 5-fluorouracil: influence of the biomodulating agents interferon, dipyridamole and folinic acid alone and in combination. Arzneimittel Forsch. 43, 387-390 (1993).
    • M. Czejka, J. Schüller, W. Jäger, U. Fogl, C. Weiss: Influence of different doses of interferon-a-2b on the blood plasma levels of 5-fluorouracil. Euro. J. Drug Metab. Ph. 18, 247-250 (1993).
    • W. Jäger*, H.P. Koch: Pharmacokinetics and organ distribution of liposome-encapsulated l-carnitine in rats. Arzneimittel Forsch. 43, 974-977 (1993).
    • W. Jäger*, H.P. Koch, B. Eisler: Pharmacokinetics and bioavailability of ß-sitosterol in rats. A comparison of three new dosage forms. Pharm. Sci. Commun., 4, 21-27 (1993).
    • J. Jirovetz, G. Ecker, W. Jäger, T. Heiss: Untersuchungen des Gehalts verschiedener Zwiebelchargen an Blei, Cadmium, Quecksilber und Selen mittels Atomabsorptions-Spektroskopie. Ernährung/Nutrition 17, 265-266 (1993).
    • W. Jäger, M. Hofeneder, E. Urban, H.P. Koch: Zytotoxische Aktivität neuer cyclischer Lactone im "Hefe-Test". Pharmazie 48, 553-554 (1993).
    • G. Buchbauer, L. Jirovetz, W. Jäger, C. Plank, H. Dietrich: Fragrance compounds and essential oils with sedative effects upon inhalation. J. Pharm. Sci. 82, 660-664 (1993).
    • H.P. Koch, W. Jäger, U. Groh, J. Hovie, G. Plank, U. Sedlak: Carbohydrates from garlic bulbs (Allium sativum L.) as inhibitor of adenosine deaminase enzyme activity. Phytother. Res. 7, 387-389 (1993).


    • M. Czejka, W. Jäger, W. Zwölfer, B. Podesser: Loop-column techniqué: a new sample clean-up method for the determination of gallopamil from biological matrix. Fresenius Z. Anal. Chem., 342, 200-20l (1992).
    • M. Czejka, W. Jäger, J. Schüller, U. Fogl, C. Weiss, H. Kienzel, A. Georgopoulos: Influence of biogradable microspheres on the local bioavailability of mitomycin after intraarterial administration. Int. J. Exptl. Clin. Chemother. 5, 29-32 (1992).
    • J. Schüller, M. Czejka, G. Schernthaner, U. Fogl, W. Jäger, M. Micksche: Influence of interferon-alpha-2b with or without folinic acid on pharmacokinetics of fluorouracil. Semin. Oncol. 19, 93-97 (1992).
    • J. Schüller, M. Czejka, G. Schernthaner, M. Wirth, C. Bosse, W. Jäger, M. Micksche: Pharmacokinetic aspects of interferon-alpha-2b after intrahepatic or intraperitoneal administration. Semin Oncol. 19, 98-104 (1992).
    • W. Jäger, G. Buchbauer, L. Jirovetz, L. Böhm, M. Fritze: Percutaneous Absorption of Lavender Oil from a Massage Oil. J. Soc. Cosmet. Chem. 43, 49-54 (1992).
    • W. Jäger, H.P. Koch, K. Pfaff: Standard allicin adsorbates on silicates. Phytother. Res. 6,149-151 (1992).
    • H.P. Koch, W. Jäger, J. Hysek, B. Körpert: Garlic and onion extracts: in vitro inhibition of adenosine deaminase. Phytother. Res. 6, 50-52 (1992).
    • G. Buchbauer, L. Jirovetz, W. Jäger: Passiflora and Lime-blossoms: Motility effects     after inhalation of the essential oils and some of the main constituents in animal     experiment. Arch. Pharm. 325, 247-248 (1992).
    • W. Jäger* , G. Buchbauer, L. Jirovetz: Evidence of the sedative effect of neroli oil, citronellal and phenylethyl acetate in mice. J. Ess. Oil Res. 4, 387-394 (1992).
    • G. Buchbauer, W. Jäger, L. Jirovetz, F. Meyer, H. Dietrich: Wirkungen von Baldrianöl, Borneol, Isoborneol, Bornylacetat und Isobornylacetat auf die Motilität von Versuchstieren (Mäusen) nach Inhalation. Pharmazie, 47 620-622 (1992).
    • H.P. Koch, W. Jäger, U. Groh, G. Plank: In vitro inhibition of adenosine desaminase by flavonoids and related compounds. New insight into the mechanism of action of plant phenolics. Meth. Find. Exp. Clin. Pharmacol. 14, 413-417 (1992).
    • L. Jirovetz, W. Jäger, H.P. Koch: Investigation of volatile constituents of the essential oil of egyptian garlic (Allium sativum L.) by means of GC-MS and GC-FTIR. Z. Lebensm. Unters. Forsch. 194, 363-365 (1992).
    • L. Jirovetz, H.P. Koch, W. Jäger, G. Remberg: Investigation of German onion oil by GC-FID, GC-MS and GC-FTIR. Pharmazie 47, 455-456 (1992).
    • L. Jirovetz, G. Buchbauer, W. Jäger, A. Woidich, A. Nikiforov: Analyses of fragrance compounds in blood samples of mice by GC-MS, GC-FTIR and GC-AES after inhalation of sandalwood oil. Biomed. Chromatogr. 6,133-134 (1992).
    • L. Jirovetz, W. Jäger, G. Remberg, J. Espinosa-Gonzales, R. Morales, A. Woidich, A. Nikiforov: Analysis of the volatiles in the seed oil of Hibiscus sabdariffa (Malvaceae) by means of GC-MS and GC-FTIR. J. Agric. Food Chem. 40, 1186-1 l87 (1992).


    • M. Czejka, J. Schüller, W. Jäger, U. Fogl, C. Weiss, A. Georgopoulos: Improvement of the local bioavailability of 5-fluorouracil II. application of hyaluronidase and clinical pharmacokinetics. Int. J. Clin. Chemother. 4, 213-217 (1991).
    • P. Chiba, T. Szekeres, W. Jäger: Determination of Pyrimidine Deoxynucleoside 1-ß-D-Arabinofuranosylcytosine Triphosphate. Eur. J. Clin. Chem. Clin. Biochem. 29, 385-389 (1991).
    • L. Jirovetz, W. Jäger, G. Buchbauer, A. Nikiforov, V. Raverdino: Investigations of animal blood samples after fragrance drug inhalation by gas chromatography/mass spectrometry with chemical ionization and selected ion monitoring. Biol. Mass Spectrom. 20, 80l-803 (1991).
    • G. Buchbauer, L. Jirovetz, W. Jäger, H. Dietrich, C. Plank, E. Karamat: Aromatherapy: evidence for sedative effects of the essential oil of lavander after inhalation. Z. Naturforsch. C, 46,1067-1072 (1991).
    • L. Jirovetz, G. Buchbauer, W. Jäger, G. Remberg, V. Raverdino, A. Nikiforov: Zur Untersuchung der Inhaltsstoffe und Wirkungen von Heublumen. Seifen-Öle-Fette-Wachse 117, 252-256 (1991).
    • L. Jirovetz, G. Buchbauer, W. Jäger, W. Balba: A simple and efficient trapping system for the investigation of exhalation samples. Fresenius Z. Anal.Chem. 340, 785-786 (1991).
    • W. Jäger*, M. Czejka, C. Seelos, J. Schüller, U. Fogl: Untersuchungen zur Zerfallskìnetik von Ftorafur. Sci. Pharm. 59, 101-106 (1991).
    • M. Czejka, W. Jäger, J. Schüller: Einfluß des Vasokonstriktors Glycylpressin auf die Verfügbarkeit von Mitomycin C. Arch. Pharm. 323, 25-27 (1991)
    • M. Czejka, W. Jäger, J. Schüller, A Teherani: Pharmakokinetik von Carboplatin nach intraperitonealer Verabreichung. Arch. Pharm. 324, I 83-184 (1991).
    • M. Czejka, W. Jäger, J. Schüller, G. Schernthaner: Pharmakokinetik und lokale Verfügbarkeit von Mitomycin C: Einfluß von Vasokonstriktion und Chemoembolisation. Arzneimittel Forsch. 41, 260-263 (1991).
    • M. Czejka, W. Jäger, J. Schüller, U. Fogl, A. D'Assie, A. Georgopoulos: Bioavailability of folinic acid in serum and red blood cells after i.v. and i.a. administration. Int. J. Exptl.Clin. Chemother. 4, 27-31 (1991).
    • M. Czejka, W. Jäger, J. Schüller, G. Schernthaner: Vergleichende Bioverfügbarkeit von 5-Fluorouracil und dem Prodrug Ftorafur nach intraarterieller, intravenöser und peroraler Verabreichung. Pharmazie 46, 587-588 (1991).
    • M. Czejka, W. Jäger, J. Schüller, U. Fogl, G. Schernthaner: Pharmakokinetische Aspekte der Kombination von Interferon-a- 2b und Folinsäure mit Fluorouracil. Arzneimittel Forsch. 41, 860-863 (1991)
    • M. Czejka, J. Schüller, W. Jäger, U. Fogl, C. Weiss, G. Schernthaner: Improvement of the local bioavailability of 5-fluorouracil I: application of biodegradable microspheres and clinical pharmacokinetics. Int. J. Exptl. Clin. Chemother. 4, 161-165 (1991).


    • L. Jirovetz, G. Buchbauer, W. Jäger, V. Raverdino, A. Nikiforov: Determination of lavander oil fragrance compounds in blood samples. Fresenius J. Anal. Chem. 338, 922-923 (1990).
    • H. Spreitzer, W. Jäger: Bestimmung von Formaldehydspuren in wässrigen Lösungen. Arch. Pharm. 323, 445-446 (1990).
    • H. Spreitzer*, W. Jäger*, M. Grimm, E. Eybl, M. Müller: Glutaraldehydrückstände Herzklappentransplantaten. Arch. Pharm. 323, 881-882 (1990).
    • H.P. Koch, W. Jäger: Knoblauch-Ölmazerate: analytische Bewertung von Knoblauchzubereitungen in öliger Lösung. Dtsch. Apoth. Ztg., 130, 2469-2474 (1990).
    • M. Czejka, W. Jäger, H. Lackner, J. Schüller: "loop-column"-Technik: ein einfaches Extraktionsverfahren zur Katecholaminbestimmung aus biologischem Material. Lab. Med. 14, 387-390 (1990).
    • W. Jäger, M. Czejka, J. Schüller, U. Fogl, E. Czejka, H. Lackner: Rapid and simple high-performance liquid chromatographic assay for 5'fluorouracil in plasma for bioavailability studies. J. Chromatogr. B 532, 411-417 (1990).
    • M. Czejka, W. Jäger, J. Schüller: Influence of hyaluronidase on the blood plasma levels of 5-fluorouracil in patients. Pharmazie 9, 693-694 (1990).
    • M. Czejka, W. Jäger, A. Georgopoulos: Pharmacokinetics of mitoxantrone in patients after 2 h and 24 h intra-arterial administration. Euro. J. Drug Metabol. Pharmacokin. 15, 219-222 (1990).


    • Georgopoulos, M. Czejka, W. Jäger, N. Starzengruber, H. Lackner: High-performance liquid chromatographic determination of teicoplanin in plasma: comparison with a microbiological assay. J. Chromatogr. B 494, 340-346 (1989).
    • M. Czejka, W. Jäger, J. Schüller: Mitomycin C determination using loop-column extraction: a rapid and sensitive high-performance liquid chromatochraphic assay for pharmacokinetic studies with spherex starch particles. J. Chromatogr. B 497, 336-341 (1989).
    • H.P. Koch, W. Jäger: Allicin-Freisetzung aus frischem und getrocknetem Knoblauch und einigen daraus hergestellten Fertigarzneimitteln. Dtsch. Apoth. Ztg.129, 273-276 (1989).
    • E. Urban, W. Jäger, H.P. Koch: Modellverbindungen fiir "Garlicin" und ihre antimikrobielle Wirksamkeit im Hefe-Wuchstest. Sci. Pharm. 57, 451-455 (1989).


    • H.P. Koch, W. Jäger: Selen im Knoblauch und in Knoblauchpräparaten. Dtsch. Apoth. Ztg. 128, 993-995 (1988).
  • Patents
    • Szekeres, T.; Handler, N.; Jäger, W.; Murias, M.; Erker T. Stilben-Derivate und deren Verwendung in Arzneimitteln. International application No.: PCT/AT 2004/000279.
    • Erker, T.; Handler, N.; Jäger, W. Kuen-Krismer, B. Parth S. Cox-II-Inhibitorenverbindungen. International application No.: PCT/AT2005/000374.
    • Szekeres, T.; Handler, N.; Jäger, W.; Murias, M.; Erker, T. Preparation of stilbens as cyclooxygenase-2 inhibitors. International application No.: PCT Int. Appl. WO 2005016860  A2  20050224 CAN 142:261298 AN 2005:158620
  • Book Chapters
    • W. Jäger: Pharmakogenetik. In: U. Jaehde, S. Mühlebach, R. Radziwill, W.Schunack (eds.) Lehrbuch der Klinischen Pharmazie (2. Auflage). Gustav Fischer, Stuttgart, 97-108 (2003)
    • W. Jäger: Pharmakogenetik. In: U. Jaehde, S. Mühlebach, R. Radziwill, W.Schunack (eds.) Lehrbuch der Klinischen Pharmazie. Gustav Fischer, Stuttgart, 72-81 (1998)